do n't let it be said that i did n't warn you finding a positive result for corlux mifepristone without having to bend reality too greatly would probably help the company if two trials failed , though , why would the current trial succeed ? sec filing below item notice of delisting or failure to satisfy a continued listing rule or standard transfer of listing nasdaq has notified corcept therapeutics incorporated that the company is not in compliance with continuous listing standards for inclusion on the nasdaq global market because i pursuant to nasdaq marketplace rule a , the company s price per share for its common stock had closed below the minimum per share requirement for consecutive business days , and ii pursuant to marketplace rule a , the company s stockholders equity reported on its form q for the period ending september , did not comply with the minimum million requirement the nasdaq notifications were provided in two letters dated november , on november , the nasdaq staff determined pursuant to marketplace rule b to adjust the period of time required for corcept to disclose the receipt of the two letters to no later than the close of business on november , pursuant to marketplace rule e , the company has a day grace period to regain compliance with nasdaq s minimum bid price requirement in order to regain compliance , the bid price of the company s common stock must close at or more per share for a minimum of consecutive business days anytime before may , nasdaq has advised the company that under marketplace rule , the company has until december , to provide nasdaq a specific plan to achieve and sustain compliance with the minimum stockholders equity standard